All In Biotech

Drug Trial Radar · NCT07309432

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Bet v 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Birch Pollen Allergy

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

24

Actual

Start

Jan 10, 2026

Primary completion

May 2, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drugs are at lowering eye allergy signs and symptoms compared with placebo. The study will also evaluate whether the combination (REGN5713-5715) has different effectiveness than REGN5713 or REGN5715 alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of the study drugs is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)

Conditions

  • Allergic Conjunctivitis

Interventions

  • REGN5713Drug

    Administered per protocol

  • REGN5715Drug

    Administered per protocol

  • PlaceboDrug

    Administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular itch score in participants receiving REGN5713-5715 compared to placeboTime frame: At Day 8 post-Conjunctival Allergen Challenge (CAC)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Andover, Massachusetts

  • Somnos Clinical Research

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.